Announcements and Sponsorships by Biotechnology Companies and Major Drug Manufacturers - Research Report on Lilly, Geron, MannKind, Techne, and InterMune Editor Note: For more information about this release, please scroll to bottom PR Newswire NEW YORK, December 2, 2013 NEW YORK, December 2, 2013 /PRNewswire/ -- Today, Analysts' Corner announced new research reports highlighting Eli Lilly & Co. (NYSE: LLY), Geron Corporation (NASDAQ: GERN), MannKind Corp. (NASDAQ: MNKD), Techne Corp. (NASDAQ: TECH), and InterMune Inc. (NASDAQ: ITMN). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Eli Lilly & Co. Research Report On November 19, 2013, Eli Lilly & Co. (Lilly) announced that Lilly Diabetes will continue its national sponsorship of the American Diabetes Association's (Association) Tour de Cure® annual cycling event for a second consecutive year. According to the Company, in 2013, more than 65,000 cyclists in 89 events across 44 states raised more than $26 million to support the mission of the Association. Additionally, the Company stated that Lilly employees, family and friends joined together nationwide form 89 teams with 954 team riders, to help raise $222,139 for people with diabetes, an increase of 211% over 2012. Commenting on the release, Kevin Cammack, Senior Director of Marketing, U.S., Lilly Diabetes and Chair of Lilly Diabetes' 2014 Corporate Campaign, stated, "Participating in this event was a moving experience for me, and I know how important it is to our employees to connect with and support people with diabetes in their own communities. We are proud to continue our support knowing that through this collaboration and with a common goal, we are helping the Association improve the lives of people with diabetes. We can't wait to get out there and ride for people with diabetes once again." The Full Research Report on Eli Lilly & Co. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/977d_LLY -- Geron Corporation Research Report On November 26, 2013, Geron Corporation (Geron) announced that the Company's President and CEO, John Scarlett, M.D., is scheduled to present an overview of the Company at the 25th Annual Piper Jaffray Healthcare Conference. According to the release, the presentation will take place on December 4, 2013, at 12:30 p.m. ET, in New York. Additionally, Geron stated that a live webcast of the presentation will be made available to interested parties and will be archived and available for replay for 30 days. The Full Research Report on Geron Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/1ca9_GERN -- MannKind Corp. Research Report On November 27, 2013, MannKind Corp. (MannKind) announced that the Company will present at The Piper Jaffray 25th Annual Healthcare Conference on December 4, 2013. According to the release, the presentation will take place at The New York Palace, New York, New York, at 10:00 a.m. ET. The Full Research Report on MannKind Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/044e_MNKD -- Techne Corp. Research Report On November 27, 2013, Techne Corp.'s (Techne) stock went down by 0.07% as it closed the day at $85.93 per share. The Company's stock went down by 1.17% over the past three trading days, compared to the Dow Jones Industrial Average which went up by 0.20% during the same period. The Full Research Report on Techne Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/b071_TECH -- InterMune Inc. Research Report On November 27, 2013, InterMune Inc.'s (InterMune) stock went up by 1.69% closing the day at $13.81 per share. Over the previous three trading day period the Company's stock went up by 6.56%, compared to the Nasdaq composite which went up by 1.33% during the same trading period. The Full Research Report on InterMune Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/dd8c_ITMN ---- EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. SOURCE Analysts' Corner Contact: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North America)
Announcements and Sponsorships by Biotechnology Companies and Major Drug Manufacturers - Research Report on Lilly, Geron,
Press spacebar to pause and continue. Press esc to stop.